Filter Results:
(13)
Show Results For
- All HBS Web (13)
- Faculty Publications (2)
Show Results For
- All HBS Web (13)
- Faculty Publications (2)
Page 1 of 13
Results
- 2015
- Working Paper
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
By: Pierre Azoulay, Joshua S. Graff Zivin, Danielle Li and Bhaven N. Sampat
We quantify the impact of scientific grant funding at the National Institutes of Health (NIH) on patenting by pharmaceutical and biotechnology firms. Our paper makes two contributions. First, we use newly constructed bibliometric data to develop a method for flexibly... View Details
Keywords: Economics Of Science; Patenting; Academic Reserach; NIH; Knowledge Spillovers; Patents; Research; Government and Politics
Azoulay, Pierre, Joshua S. Graff Zivin, Danielle Li, and Bhaven N. Sampat. "Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules." Harvard Business School Working Paper, No. 16-056, October 2015.
- 2015
- Working Paper
Expertise vs. Bias in Evaluation: Evidence from the NIH
By: Danielle Li
Evaluators with expertise in a particular field may have an informational advantage in separating good projects from bad. At the same time, they may also have personal preferences that impact their objectivity. This paper develops a framework for separately identifying... View Details
Li, Danielle. "Expertise vs. Bias in Evaluation: Evidence from the NIH." Harvard Business School Working Paper, No. 16-053, October 2015.
- 11 Nov 2015
- Working Paper Summaries
Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules
- 01 Dec 2010
- News
Chaotic Funding Derails Research
postdoctoral students who are pursuing careers in science. Labs have many different projects under investigation simultaneously. Most labs have annual budgets of $1 million to $5 million, with most of that money coming from grants from institutions like the National... View Details
- 26 Feb 2020
- News
Alumni-Led Biotech Developing Vaccine to Combat Coronavirus
As reported in the Boston Globe, Stéphane Bancel (MBA 2000, AMP 170) and his firm Moderna Therapeutics are working with the National Institutes of Health (NIH) to develop a vaccine for coronavirus. Vials of its vaccine, the company told the Globe, have been sent to the... View Details
- 05 Jan 2011
- Op-Ed
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress
million to $5 million, with most of that money coming from grants from institutions like the National Institutes of Health (NIH). “Funding can be canceled with the stroke of a pen.” The NIH allocates money to researchers whose proposals... View Details
- 22 Feb 2022
- News
Elevator Pitch: Good Vibrations
won’t take those medications due to side effects. There’s a real gap for a simple treatment you can use earlier in the disease trajectory.” Status Update: The grand prize winner in the Alumni New Venture Competition, Bone Health Technologies has been awarded $4.7... View Details
- 01 Mar 2016
- News
Research Brief: The Benefits of Bias
NIH grant applications from 1992 to 2005. She plotted links between applicants and evaluators—via professional publication citations—to determine potential bias. Then, to establish the quality of the funded projects, she tracked the... View Details
Keywords: Erin Peterson
- 03 Nov 2015
- First Look
November 3, 2015
successfully navigate their academic careers. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=50056 Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules By: Azoulay, Pierre, Joshua S.... View Details
Keywords: Sean Silverthorne
- 01 Jun 2000
- News
Managing the Map
precisely target individual diseases. Isolating the genome's three billion chemical units is a task of such immense scope that the NIH formed a consortium of academic and government research laboratories to undertake the work... View Details
Keywords: Peter K. Jacobs
- 24 Sep 2020
- News
The Race for a Vaccine
newly opened facility to accommodate its vaccine development work, and CEO Stéphane Bancel (MBA 2000, AMP 170) welcomed input on the design from the government’s infectious disease experts. For two years, Moderna had been working closely with the View Details
- 28 Nov 2016
- Research & Ideas
Challenging the Belief that Liability Laws Kill Medical Device Innovation
bottom line of medical device companies—it’s good for patients as well. Related Reading: New Medical Devices Get To Patients Too Slowly Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules Five... View Details
- 01 Mar 2013
- News
Making Change
centers. We've raised $500,000 through private angels and grants from the government of India and the NIH in the United States. What's been an important move that you've made? Building the core team has been critical because diabetes is... View Details